EC Clinical and Medical Case Reports

The relevance of the search for new therapeutic approaches to stabilizing atherosclerotic plaques is due to the particular importance of this disease for human life. The main problems for clinicians remain not only the prevention of the formation of intravascular infiltrations of cholesterol in the intima of blood vessels (since this is a biological process), but the prevention of the transition of formed plaques to an unstable state. According to immunomorphological studies, the formed plaque undergoes constant cellular and humoral dynamics under the influence of active intracellular efferocytosis [1].

1. Pigarevsky PV. “Unstable atherosclerotic plaque (immunomorphological study)”. Atlas - St. Petersburg, Spetslit (2018): 148.
2. Amir Tajbakhsh., et al. “Efferocytosis in atherosclerotic lesions: Malfunctioning regulatory pathways and control mechanisms”. Pharmacology and Therapeutics 188 (2018): 12-25.
3. Jarr KU., et al. “The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis”. Nature Cardiovascular Research3 (2022): 253-262.
4. Zidar DA. “Rate of Statin Prescription in Younger Patients with Severe Dyslipidemia”. The Journal of the American Medical Association Cardiology (2017).
5. Catapano A., et al. “ESC/EAS Guidelines for the Management of Dyslipidaemias”. European Heart Journal39 (2016): 2999-3058.
6. Nidorf SM., et al. “Colchicine in Patients with Chronic Coronary Disease”. The New England Journal of Medicine 383 (2020): 1838-1847.
7. Katyukhin VN., et al. “Patent for invention No. 2339317 dated November 27, 2008. “Method for protecting the myocardium and blood vessels during intracoronary interventions” was registered in the State Register of Inventions of the Russian Federation (2008).